Compare Extra Space Storage, Inc. (EXR) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Extra Space Storage, Inc. vs GSK plc — how do they compare? Extra Space Storage, Inc. trades at $133.85 (market cap $28.12B), while GSK plc trades at $46.66 (market cap $91.88B). The key difference: GSK plc is far larger — about 3.3× Extra Space Storage, Inc.'s market cap, and Extra Space Storage, Inc. pays the higher dividend (4.87%). Which is the better fit depends on your goals — on Pluang, investors hold Extra Space Storage, Inc. for 109 Days and GSK plc for 93 Days on average.
| EXR | GSK | |
|---|---|---|
Market Cap | $28.12B | $91.88B |
Volume | 2,595,579 | 7,730,529 |
Sector | Real Estate | Health |
52-Week High | $152.85 | $61.18 |
52-Week Low | $126.67 | $43.24 |
Typical Hold Time | 109 Days | 93 Days |
Enterprise Value | $41.84B | $111.88B |
Dividend Yield | 4.87% | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Extra Space Storage (EXR) trades at $134.22, up 1.91% today, with a bearish technical signal but strong fundamentals including a 27.79% net income margin and consistent earnings beats. The company reported $3.38B in 2025 revenue, with a P/E of 29.39 and a consensus price target of $158.33. Recent news highlights executive leadership transition and a Q3 2026 earnings call scheduled for October 27, 2026.
Outlook is mixed: analyst consensus is evenly split between Buy and Hold, with upside potential from operational strength, but risks include high debt levels and bearish technical indicators. The stock offers a dividend yield supported by stable cash flows, though macroeconomic sensitivity and valuation premiums warrant caution.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Extra Space Storage, Inc.
Extra Space Storage is a fully integrated real estate investment trust that owns, operates, and manages almost 2,100 self-storage properties in 41 states, with over 160 million net rentable square feet of storage space. Of these properties, approximately one half is wholly owned, while some facilities are owned through joint ventures and others are owned by third parties and managed by Extra Space Storage in exchange for a management fee.
Read more on EXR →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
